ACH

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Owens & Minor, Inc. (Note: The request metadata listed "Accendra Health Inc," but the source text is for Owens & Minor, Inc.) for the quarterly period ended June 30, 2005. The company is a leading distributor of medical and surgical supplies and equipment. The reporting period includes the impact of the January 31, 2005, acquisition of Access Diabetic Supply, LLC, a direct-to-consumer distributor of diabetic supplies.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 8% year-over-year for both the quarter and the six-month period. Organic growth (excluding acquisitions) was 7%, driven by higher sales volume to existing and new customers.
• Profitability: Net income rose 4% for the quarter and 6% for the six-month period compared to 2004. Operating earnings increased 3% and 5%, respectively.
• Margins: Gross margin percentage improved to 10.6% from 10.3% in the prior year, primarily due to the higher-margin Access Diabetic Supply business. However, this was partially offset by lower supplier incentives.
• Expenses: Selling, general, and administrative (SG&A) expenses increased to 7.9% of revenue from 7.6% in 2004, reflecting the higher expense structure of the new direct-to-consumer segment.
• Cash Flow: Operating cash flow for the six months ended June 30, 2005, was $121.4 million, a significant increase from $71.1 million in the prior year, driven by a $27.9 million reduction in inventory.

Guidance, Outlook, Risks, and Unusual Items

• Acquisitions: The company spent approximately $60.6 million on acquisitions in the first six months of 2005, primarily for Access Diabetic Supply ($57.9 million), Direct Diabetic Supplies ($1.6 million), and Cyrus Medical Systems ($1.0 million).
• Capital Expenditures: CapEx was $15.6 million for the six months, up from $7.7 million in 2004, largely due to the construction of a new corporate headquarters.
• Accounting Changes: The company will adopt SFAS 123R (Share-Based Payment) on January 1, 2006. This is expected to have a material effect on results of operations by requiring fair value recognition of stock-based compensation, though the exact impact depends on future grant levels.
• Tax Contingency: The IRS proposed disallowing certain LIFO inventory valuation reductions effective for 2001 and subsequent years. If unsuccessful in its appeal, the company faces a potential tax deficiency of approximately $41.1 million plus interest (approx. $4.7 million as of June 30, 2005). No reserve has been established.
• Liquidity: The company maintains strong liquidity with $74.1 million in cash and $240.7 million in unused credit under its revolving facility.

Investor Verification Checklist

• IRS LIFO Dispute: Verify the status of the appeal regarding the $41.1 million potential tax deficiency and the likelihood of a cash outflow.
• Access Diabetic Supply Integration: Monitor the performance of the new direct-to-consumer segment to ensure it sustains the reported gross margin improvements.
• Supplier Incentives: Track the trend of supplier incentives and alternate source purchasing, as lower contributions in 2005 negatively impacted gross margins.
• Inventory Management: Confirm the sustainability of the $27.9 million inventory reduction that drove the strong operating cash flow.
• Goodwill Impairment: Assess the risk of goodwill impairment given the significant increase in goodwill ($38.5 million added in six months) and the competitive healthcare environment.